Case Report: Ocular Adverse Effects Occurring with Mirvetuximab Soravtansine-gynx
Clinical Insights in Eyecare · 02.04.2026 · 4 (1)
DOI: 10.66574/001c.159988 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Insights in Eyecare, online erschienen am 02.04.2026. Verfasst von Kristen P. Lamoreau und 1 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Real-world ocular adverse events and collaborative management are described in a representative patient with platinum-resistant ovarian cancer treated with mirvetuximab soravtansine-gynx, a folate receptor alpha-targeting antibody-drug conjugate that showed significant survival and clinical benefits over chemotherapy in the MIRASOL trial. Case Report A representative case was selected from 26 mirvetuximab soravtansine-gynx–treated patients with platinum-resistant ovarian cancer referred to the Beth Israel Deaconess Medical Center Ophthalmology Division. The patient was evaluated before initiation and after every other mirvetuximab soravtansine-gynx infusion, unless a more frequent follow-up was indicated and the patient received prophylactic topical corticosteroid and daily lubricating eye drops. The patient experienced epithelial keratopathy with grade 3 reduction in best-corrected distance visual acuity, necessitating a pause in treatment. Keratopathy improved thereafter, but recurred after reintroduction at a lower dose, leading to further dose reduction before findings eventually cleared and best-corrected distance visual acuity improved.
Conclusion
This case demonstrates the clinical course of ocular adverse events in a patient receiving mirvetuximab soravtansine-gynx with dose delay or adjustment.
Zitieren
APA
Lamoreau, K. P., & You, J. Y. (2026). Case Report: Ocular Adverse Effects Occurring with Mirvetuximab Soravtansine-gynx. Clinical Insights in Eyecare, 4(1). https://doi.org/10.66574/001c.159988
Vancouver
Lamoreau KP, You JY. Case Report: Ocular Adverse Effects Occurring with Mirvetuximab Soravtansine-gynx. Clinical Insights in Eyecare. 2026;4(1). doi:10.66574/001c.159988
BibTeX
@article{Lamoreau2026,
author = {Lamoreau, Kristen P. and You, Jae Young},
title = {Case Report: Ocular Adverse Effects Occurring with Mirvetuximab Soravtansine-gynx},
journal = {Clinical Insights in Eyecare},
year = {2026},
volume = {4},
number = {1},
doi = {10.66574/001c.159988}
}
EUVIMED